CY-09
Based on 51 publication(s) in Google Scholar
CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation.
For research use only. We do not sell to patients.
- Purity: 99.01%
- CAS No.: 1073612-91-5
- Formula: C19H12F3NO3S2
- Molecular Weight:423.43
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
NF-κB Signaling Compound Library
HY-L014
-
Covalent Screening Library
HY-L036
-
Antioxidant Compound Library
HY-L037
-
Anti-diabetic Compound Library
HY-L040
-
Oxygen Sensing Compound Library
HY-L045
-
Pyroptosis Compound Library
HY-L059
-
Targeted Diversity Library
HY-L099
-
Antidepressant Compound Library
HY-L108
-
Heterocyclic Compound Library
HY-L138
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Highly Selective Inhibitors Library
HY-L158
-
Inflammasomes related Compound Library
HY-L175
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Pattern Recognition Receptors Library
HY-L237
-
Immunology/Inflammation Compound Library
HY-L007
Publications Citing Use of MedChemExpress (MCE) CY-09
More- Cell Res. 2025 Apr 1. [Abstract]
- Exploration. 2025 Dec 18;5(6):20240396. [Abstract]
- Blood. 2020 Jul 23;136(4):501-515. [Abstract]
- Bioact Mater. 2025 Sep 19:55:205-223. [Abstract]
- Nat Commun. 2026 May 27. [Abstract]
- Nat Commun. 2025 Jul 2;16(1):6074. [Abstract]
- Nat Commun. 2025 May 27;16(1):4887. [Abstract]
- Mol Biomed. 2025 Nov 13;6(1):108. [Abstract]
- Chem Eng J. 1 May 2022, 135115.
- Engineering. 2025 Aug 14.
- Pharmacol Res. 2025 Apr:214:107676. [Abstract]
- Cancer Lett. 2023 Oct 28:575:216403. [Abstract]
- Cell Commun Signal. 2024 Aug 21;22(1):408. [Abstract]
- Int J Biol Macromol. 2025 Apr:301:140133. [Abstract]
- Free Radic Biol Med. 2022 Mar:181:29-42. [Abstract]
- Cell Rep. 2025 Dec 10;44(12):116673. [Abstract]
- Br J Pharmacol. 2020 Jun;177(12):2726-2742. [Abstract]
- Atherosclerosis. 2023 Dec:387:117391. [Abstract]
- Atherosclerosis. 2022 Apr:347:28-38. [Abstract]
- Front Immunol. 2021 Sep 22:12:749979. [Abstract]
- Neurosci Bull. 2025 Jul 20. [Abstract]
- Neurosci Bull. 2020 Sep;36(9):1035-1045. [Abstract]
- Ecotoxicol Environ Saf. 2023 Oct 1:264:115385. [Abstract]
- Cell Mol Life Sci. 2025 Nov 6;82(1):388. [Abstract]
- Life Sci. 2024 Dec 1:358:123128. [Abstract]
- Eur J Pharmacol. 2025 Jul 5:998:177512. [Abstract]
- Int J Mol Sci. 2025 Jan 9;26(2):520. [Abstract]
- Int Immunopharmacol. 2022 Dec;113(Pt B):109430. [Abstract]
- Int Immunopharmacol. 2022 Nov:112:109176. [Abstract]
- Mol Neurobiol. 2022 Nov;59(11):6934-6955. [Abstract]
- Inflammation. 2024 Jun;47(3):1028-1040. [Abstract]
- Sci Rep. 2026 Mar 16;16(1):13654. [Abstract]
- Eur J Med Res. 2025 Jul 1;30(1):541. [Abstract]
- Environ Toxicol Pharmacol. 2025 Jun:116:104706. [Abstract]
- J Inflamm Res. 2021 Dec 7;14:6601-6618. [Abstract]
- iScience. 2021 Sep 25;24(10):103170. [Abstract]
- J Virol. 2025 Dec 23;99(12):e0146625. [Abstract]
- J Funct Foods. 2021, 104584.
- Neuromolecular Med. 2025 Mar 7;27(1):22. [Abstract]
- Biochim Biophys Acta Mol Cell Biol Lipids. 2024 Mar;1869(2):159428. [Abstract]
- J Orthop Surg Res. 2022 Nov 16;17(1):487. [Abstract]
- Mol Immunol. 2023 Mar:155:7-16. [Abstract]
- Immunopharmacol Immunotoxicol. 2021 Dec;43(6):778-789. [Abstract]
- Vet Microbiol. 2024 Nov:298:110243. [Abstract]
- Vet Microbiol. 2023 Sep:284:109825. [Abstract]
- Hum Cell. 2022 Nov;35(6):1752-1765. [Abstract]
- Med Sci Monit. 2020 Sep 21:26:e925491. [Abstract]
- Neuroreport. 2023 Sep 6;34(13):670-676. [Abstract]
- Research Square Preprint. 2023 Oct 11.
- SSRN. 2023 Sep 15.
- Biomed Pharmacother. 2022 Jul;151:113098. [Abstract]
Customer Validation & Images
-
WB
-
WB
-
IF
-
WB
-
RT-PCR
Biological Activity
|
NLRP3 |
CY-09 exhibits a dose-dependent inhibitory effect on monosodium urate (MSU), nigericin, ATP-induced caspase-1 activation and IL-1β secretion at the doses of 1 to10 μM in LPS-primed bone marrow-derived macrophages (BMDMs). Cytosolic LPS-induced noncanonical NLRP3 activation in BMDMs can also be blocked by CY-09 treatment. CY-09 specifically inhibits NLRP3 inflammasome activation and has no effect on LPS-induced priming effects. CY-09 treatment remarkably suppresses nigericin-induced ASC oligomerization. It is found that CY-09 treatment inhibits the interaction of Flag-NLRP3 and mCherry-NLRP3 in HEK-293T cells, suggesting that CY-09 blocks NLRP3 oligomerization[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1073612-91-5
-
Appearance Solid
-
Molecular Weight 423.43
-
Formula C19H12F3NO3S2
-
Color Light yellow to yellow
-
SMILES
OC(C1=CC=C(/C=C2SC(N(CC3=CC=CC(C(F)(F)F)=C3)C\2=O)=S)C=C1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (51)
-
Journal Impact Factor
-
Most Recent
-
Cell Res
2025 Apr 1. PMID: 40164768
CY-09 purchased from MedChemExpress. Usage Cited in: Cell Res. 2025 Apr 1. [Abstract]
CY-09 (20 μM; 30 min) blocked NLRP3 inflammasome activation in THP-1 cells.
CY-09 purchased from MedChemExpress. Usage Cited in: Cell Res. 2025 Apr 1. [Abstract]
CY-09 (20 μM; 30 min) suppressed NLRP3 activation induced by 1,5-PD and 1,2-PD in THP-1 cells.
-
Exploration
A Bioorthogonal and Programmable Bacterial Delivery System for Spatiotemporally Targeted Therapy of Solid Tumors. [Abstract]2025 Dec 18;5(6):20240396. PMID: 41476656 -
Blood
The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice. [Abstract]2020 Jul 23;136(4):501-515. PMID: 32291445
CY-09 purchased from MedChemExpress. Usage Cited in: Blood. 2020 Jul 23;136(4):501-515. [Abstract]
CY-09 (1 μM; 24 h) suppressed TMAO-induced mRNA expression of M1 signature cytokines or chemokines in BMDMs, including IL-1β, IL-6, TNF-α, CXCL9, and CXCL10.
CY-09 purchased from MedChemExpress. Usage Cited in: Blood. 2020 Jul 23;136(4):501-515. [Abstract]
CY-09 (1 μM; 24 h) markedly decreased the concentrations of IL-1β in the supernatant of BMDMs.
CY-09 purchased from MedChemExpress. Usage Cited in: Blood. 2020 Jul 23;136(4):501-515. [Abstract]
CY-09 (1 μM; 24 h). Flow cytometry analysis of FLICA Casapse-1 in BMDMs was determined.
-
Bioact Mater
An intelligent nanoreservoir system promotes heart valve regeneration via ROS scavenging and immunomodulation. [Abstract]2025 Sep 19:55:205-223. PMID: 41035431 -
Nat Commun
African swine fever virus B66L drives extracellular mitochondrial release to promote systemic inflammation in mice. [Abstract]2026 May 27. PMID: 42203763 -
Nat Commun
Mast cells boost anti-tumor potency of MAIT cells via inflammasome-dependent secretion of IL-18. [Abstract]2025 Jul 2;16(1):6074. PMID: 40603850 -
Nat Commun
Clustering of NLRP3 induced by membrane or protein scaffolds promotes inflammasome assembly. [Abstract]2025 May 27;16(1):4887. PMID: 40425567 -
Mol Biomed
ML345 is a potent and selective NLRP3 inflammasome inhibitor with anti-inflammatory activity. [Abstract]2025 Nov 13;6(1):108. PMID: 41231359 -
-
-
Pharmacol Res
Cardiac fibroblast-derived mitochondria-enriched sEVs regulate tissue inflammation and ventricular remodeling post-myocardial infarction through NLRP3 pathway. [Abstract]2025 Apr:214:107676. PMID: 40015386 -
Cancer Lett
FABP4 in macrophages facilitates obesity-associated pancreatic cancer progression via the NLRP3/IL-1β axis. [Abstract]2023 Oct 28:575:216403. PMID: 37741433 -
Cell Commun Signal
IL-1β mediates Candida tropicalis-induced immunosuppressive function of MDSCs to foster colorectal cancer. [Abstract]2024 Aug 21;22(1):408. PMID: 39164774 -
Int J Biol Macromol
Chlorogenic acid mitigates heat stress-induced oxidative damage in bovine mammary epithelial cells by inhibiting NF-κB-mediated NLRP3 inflammasome activation via upregulating the Nrf2 signaling pathway. [Abstract]2025 Apr:301:140133. PMID: 39842566 -
Free Radic Biol Med
Protective role of hydrogen sulfide against diabetic cardiomyopathy via alleviating necroptosis. [Abstract]2022 Mar:181:29-42. PMID: 35101564 -
Cell Rep
Aryl hydrocarbon receptor-induced activation of AIM2 inflammasome is mediated by MOMP and MPT: A vital therapeutic pathway for inflammation. [Abstract]2025 Dec 10;44(12):116673. PMID: 41385364 -
Br J Pharmacol
Cathelicidin-related antimicrobial peptide protects against ischaemia reperfusion-induced acute kidney injury in mice. [Abstract]2020 Jun;177(12):2726-2742. PMID: 31976546 -
Atherosclerosis
RhoGDI3 at the trans-Golgi network participates in NLRP3 inflammasome activation, VSMC phenotypic modulation, and neointima formation. [Abstract]2023 Dec:387:117391. PMID: 38029612 -
Atherosclerosis
Blocking the NLRP3 inflammasome reduces osteogenic calcification and M1 macrophage polarization in a mouse model of calcified aortic valve stenosis. [Abstract]2022 Apr:347:28-38. PMID: 35299058 -
Front Immunol
NLRP3 Inflammasome Activation of Mast Cells by Estrogen via the Nuclear-Initiated Signaling Pathway Contributes to the Development of Endometriosis. [Abstract]2021 Sep 22:12:749979. PMID: 34630429 -
Neurosci Bull
Single-Cell Sequencing Reveals Circadian Sensitivity of Noise-Induced Hearing Loss Mediated by Macrophage-Driven NLRP3 Inflammasome Activation. [Abstract]2025 Jul 20. PMID: 40684422 -
Neurosci Bull
Macrophage-NLRP3 Inflammasome Activation Exacerbates Cardiac Dysfunction after Ischemic Stroke in a Mouse Model of Diabetes. [Abstract]2020 Sep;36(9):1035-1045. PMID: 32683554 -
Ecotoxicol Environ Saf
DBP exposure induces thyroid inflammatory impairment through activating AKT/NF-κB/NLRP3 signaling. [Abstract]2023 Oct 1:264:115385. PMID: 37625334 -
Cell Mol Life Sci
2025 Nov 6;82(1):388. PMID: 41196415 -
Life Sci
Enhanced oxidative stress aggravates BLM-induced pulmonary fibrosis by promoting cellular senescence through enhancing NLRP3 activation. [Abstract]2024 Dec 1:358:123128. PMID: 39393575 -
Eur J Pharmacol
Steroid constituents of Solidago canadensis alleviate LPS-induced inflammation via AMPK regulated mitophagy/NLRP3 and NF-κB pathway. [Abstract]2025 Jul 5:998:177512. PMID: 40113066 -
Int J Mol Sci
HERV-W Env Induces Neuron Pyroptosis via the NLRP3-CASP1-GSDMD Pathway in Recent-Onset Schizophrenia. [Abstract]2025 Jan 9;26(2):520. PMID: 39859234 -
Int Immunopharmacol
Candida tropicalis induces NLRP3 inflammasome activation via glycogen metabolism-dependent glycolysis and JAK-STAT1 signaling pathway in myeloid-derived suppressor cells to promote colorectal carcinogenesis. [Abstract]2022 Dec;113(Pt B):109430. PMID: 36384075
CY-09 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2022 Dec;113(Pt B):109430. [Abstract]
CY09 remarkably inhibits the infiltration of CD11b+ myeloid cells in colon tumors of C. tropicalis-gavaged CAC mice.
-
Int Immunopharmacol
Protective effect of ginsenoside Rh2 against Toxoplasma gondii infection-induced neuronal injury through binding TgCDPK1 and NLRP3 to inhibit microglial NLRP3 inflammasome signaling pathway. [Abstract]2022 Nov:112:109176. PMID: 36067653 -
Mol Neurobiol
Isobavachalcone's Alleviation of Pyroptosis Contributes to Enhanced Apoptosis in Glioblastoma: Possible Involvement of NLRP3. [Abstract]2022 Nov;59(11):6934-6955. PMID: 36053436 -
Inflammation
METTL3 Modulates TXNIP Expression to Affect the Activation of NLRP3 Inflammasome in Hepatic Cells Under Oxygen-Glucose Deprivation/Reperfusion Injury. [Abstract]2024 Jun;47(3):1028-1040. PMID: 38236385 -
Sci Rep
Molecular and spatial heterogeneity of macrophage like vascular smooth muscle cells in abdominal aortic aneurysms associated with intraluminal thrombus. [Abstract]2026 Mar 16;16(1):13654. PMID: 41839967 -
Eur J Med Res
Identification of the pyroptosis, apoptosis, and necroptosis (PANoptosis) involved in osteogenic differentiation inhibition impaired by tumor necrosis factor-α. [Abstract]2025 Jul 1;30(1):541. PMID: 40597297 -
Environ Toxicol Pharmacol
Construction of a toxicity pathway from activation of the TLR4/NF-κB/NLRP3 axis to Parkinson's disease-like non-motor symptoms in mice. [Abstract]2025 Jun:116:104706. PMID: 40306475 -
J Inflamm Res
Chinese Herbal Medicine Suyin Detoxification Granule Inhibits Pyroptosis and Epithelial-Mesenchymal Transition by Downregulating MAVS/NLRP3 to Alleviate Renal Injury. [Abstract]2021 Dec 7;14:6601-6618. PMID: 34908861 -
iScience
2021 Sep 25;24(10):103170. PMID: 34646996 -
J Virol
Avian coronavirus IBV-induced activation of the NLRP3-Caspase-1-IL-1β axis in renal collecting ducts contributes to nephropathogenesis. [Abstract]2025 Dec 23;99(12):e0146625. PMID: 41334910 -
-
Neuromolecular Med
SP3-Mediated Transcriptional Activation of GRIK1 is Involved in Alzheimer's Disease-Induced Cognitive Decline by Inducing Inflammasome Activation in Microglia. [Abstract]2025 Mar 7;27(1):22. PMID: 40055261 -
Biochim Biophys Acta Mol Cell Biol Lipids
Palmitic acid activates NLRP3 inflammasome through NF-κB and AMPK-mitophagy-ROS pathways to induce IL-1β production in large yellow croaker (Larimichthys crocea). [Abstract]2024 Mar;1869(2):159428. PMID: 38029958 -
J Orthop Surg Res
Daphnoretin relieves IL-1β-mediated chondrocytes apoptosis via repressing endoplasmic reticulum stress and NLRP3 inflammasome. [Abstract]2022 Nov 16;17(1):487. PMID: 36384642
CY-09 purchased from MedChemExpress. Usage Cited in: J Orthop Surg Res. 2022 Nov 16;17(1):487. [Abstract]
Daphnoretin or CY-09 markedly attenuates the expression of COX-2, iNOS, TNF-α, IL-6, PGE2 and the NLRP3-ASC-Caspase1 infammasome in ATDC5 cells.
-
Mol Immunol
CoQ10 alleviates hepatic ischemia reperfusion injury via inhibiting NLRP3 activity and promoting Tregs infiltration. [Abstract]2023 Mar:155:7-16. PMID: 36640727 -
Immunopharmacol Immunotoxicol
Capillin protects against non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation and oxidative stress. [Abstract]2021 Dec;43(6):778-789. PMID: 34618611 -
Vet Microbiol
2024 Nov:298:110243. PMID: 39299011 -
Vet Microbiol
PRRSV inhibited the proliferation of CSFV by inducing IL-1β maturation via NLRP3 inflammasome activation. [Abstract]2023 Sep:284:109825. PMID: 37453262 -
Hum Cell
FOSL2 deficiency delays nonalcoholic steatohepatitis progression by regulating LY6D-mediated NLRP3 activation. [Abstract]2022 Nov;35(6):1752-1765. PMID: 35930135 -
Med Sci Monit
P2X7 Receptor (P2X7R) of Microglia Mediates Neuroinflammation by Regulating (NOD)-Like Receptor Protein 3 (NLRP3) Inflammasome-Dependent Inflammation After Spinal Cord Injury. [Abstract]2020 Sep 21:26:e925491. PMID: 32952148 -
Neuroreport
NDUFC2 deficiency exacerbates endothelial mesenchymal transformation during ischemia-reperfusion via NLRP3. [Abstract]2023 Sep 6;34(13):670-676. PMID: 37506315 -
-
-
Biomed Pharmacother
Dendrobium officinale polysaccharides attenuate uropathogenic Escherichia coli (UPEC)-induced pyroptosis in macrophage cells. [Abstract]2022 Jul;151:113098. PMID: 35594714
Solvent & Solubility
DMSO : ≥ 150 mg/mL (354.25 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 1.5 mg/mL (3.54 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
For ATPase activity assay, purified recombinant human proteins are incubated at 37°C with indicated concentrations of CY-09 for 15 min in the reaction buffer. ATP (25 µm) is then added, and the mixture is further incubated at 37°C for another 40 min. The amount of ATP converted into adenosine diphosphate (ADP) is determined by luminescent ADP detection with ADP-Glo Kinase Assay kit according to the manufacturer’s protocol. The results are expressed as percentage of residual enzyme activity to the vehicle-treated enzyme. For ATP binding assay, purified NLRP3 proteins are incubated with ATP binding agarose for 1 h and then different concentrations of CY-09 are added and incubated for 2 h with motion at 4°C. Beads are washed and boiled in loading buffer. Samples are subjected to immunoblotting analysis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
To induce NLRP3 inflammasome activation, 5×105/mL BMDMs and 6×106/mL PBMCs are plated in 12-well plates. The following morning, the medium is replaced, and cells are stimulated with 50 ng/mL LPS or 400 ng/mL Pam3CSK4 (for noncanonical inflammasome activation) for 3 h. After that, CY-09 or other inhibitors are added into the culture for another 30 min, and then the cells are stimulated for 4 h with monosodium urate (MSU) (150 µg/mL), Salmonella typhimurium (multiplicity of infection) or for 30 min with ATP (2.5 mM) or nigericin (10 µM). Cells are transfected with poly(dA:dT) (0.5 µg/mL) for 4 h or LPS (500 ng/mL) overnight. Cell extracts and precipitated supernatants are analyzed by immunoblot[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
WT or Nlrp3−/− mice at the age of 6 wk, with similar plasma glucose levels and body weights are randomized into different groups. For generation of high-fat diet (HFD)-induced diabetic mice, mice are fed with HFD for 14 wk. The diabetic mice are treated with CY-09 (i.p.) at a dose of 2.5 mg/kg once a day for 6 wk. The mice are maintained with HFD when used for CY-09 treatment and the subsequent experiments[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3617 mL | 11.8083 mL | 23.6167 mL | 59.0416 mL |
| 5 mM | 0.4723 mL | 2.3617 mL | 4.7233 mL | 11.8083 mL | |
| 10 mM | 0.2362 mL | 1.1808 mL | 2.3617 mL | 5.9042 mL | |
| 15 mM | 0.1574 mL | 0.7872 mL | 1.5744 mL | 3.9361 mL | |
| 20 mM | 0.1181 mL | 0.5904 mL | 1.1808 mL | 2.9521 mL | |
| 25 mM | 0.0945 mL | 0.4723 mL | 0.9447 mL | 2.3617 mL | |
| 30 mM | 0.0787 mL | 0.3936 mL | 0.7872 mL | 1.9681 mL | |
| 40 mM | 0.0590 mL | 0.2952 mL | 0.5904 mL | 1.4760 mL | |
| 50 mM | 0.0472 mL | 0.2362 mL | 0.4723 mL | 1.1808 mL | |
| 60 mM | 0.0394 mL | 0.1968 mL | 0.3936 mL | 0.9840 mL | |
| 80 mM | 0.0295 mL | 0.1476 mL | 0.2952 mL | 0.7380 mL | |
| 100 mM | 0.0236 mL | 0.1181 mL | 0.2362 mL | 0.5904 mL |
CY-09 Related Classifications
HY-103666 Related Classifications
Powered by Bioz